Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service
Open Access
- 25 November 2024
- journal article
- review article
- Published by Wiley in Head & Neck
- Vol. 47 (2) , 733-741
Abstract
Background: Oral potentially malignant disorders (OPMDs) occur in up to 4%–5% of the population, of which oral leukoplakia (OL) is the most common subtype. Predicting high‐risk OL remains a challenge. Early diagnosis and effective treatment are thought to be of paramount importance to improve outcomes.Methods: We searched PubMed and Clinicaltrials.gov data for updates in the clinical management of OL from 2015 to current.Results: Recent publication of large cohorts of patients with OL aids in counseling patients regarding risk of malignant transformation. Management for OL includes surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention. Several new entities show promise regarding candidate biomarkers, chemoprevention agents, and diagnostic adjuncts, though all require further validation.Conclusion: This update serves to further inform clinical management of OL and provide impetus for future investigations.Trial Registration: NCT00099021, NCT00951379, NCT05727761, NCT05727761Keywords
This publication has 86 references indexed in Scilit:
- Cannabis Use and Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2024
- Nivolumab for Patients With High-Risk Oral LeukoplakiaJAMA Oncology, 2024
- Clinical outcomes of oral epithelial dysplasia managed by observation versus excisionHead & Neck, 2023
- Predicting Progression of Oral Lesions to Malignancy Using Machine LearningThe Laryngoscope, 2022
- An active surveillance program in oral preneoplasia and translational oncology benefitLaryngoscope Investigative Otolaryngology, 2021
- Binary and WHO dysplasia grading systems for the prediction of malignant transformation of oral leukoplakia and erythroplakia: a systematic review and meta-analysisClinical Oral Investigations, 2021
- Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta‐analysis of malignant transformation rate by subtypeHead & Neck, 2019
- Erlotinib and the Risk of Oral CancerJAMA Oncology, 2016
- Photodynamic Therapy for Head and Neck Dysplasia and CancerJAMA Otolaryngology–Head & Neck Surgery, 2009
- Treatment and follow‐up of oral dysplasia — A systematic review and meta‐analysisHead & Neck, 2009